[go: up one dir, main page]

PE20080370A1 - Derivados de quinazolinona como antagonistas de cgrp - Google Patents

Derivados de quinazolinona como antagonistas de cgrp

Info

Publication number
PE20080370A1
PE20080370A1 PE2007000697A PE2007000697A PE20080370A1 PE 20080370 A1 PE20080370 A1 PE 20080370A1 PE 2007000697 A PE2007000697 A PE 2007000697A PE 2007000697 A PE2007000697 A PE 2007000697A PE 20080370 A1 PE20080370 A1 PE 20080370A1
Authority
PE
Peru
Prior art keywords
cgrp
antagonists
quinazolinone derivatives
salts
compound
Prior art date
Application number
PE2007000697A
Other languages
English (en)
Inventor
Henri Doods
Kirsten Arndt
Thierry Bouyssou
Stephan Georg Muller
Klaus Rudolf
Gerhard Schanzle
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37101671&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20080370(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PE20080370A1 publication Critical patent/PE20080370A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

REFERIDA A UN DERIVADO DE QUINAZOLINONA DE FORMULA (A), SUS ENANTIOMEROS, DIASTEREOMEROS, MEZCLAS Y SALES DE LOS MISMOS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE DICHO COMPUESTO O SUS SALES. DICHO COMPUESTO ES ANTAGONISTA DE LA ACTIVIDAD DE LAS FIBRAS C AFERENTES QUE CONTIENEN PEPTIDO RELACIONADO CON EL GEN CALCITONINA (CGRP) Y ES UTIL EN EL TRATAMIENTO DE TRASTORNOS GASTROINTESTINALES
PE2007000697A 2006-06-08 2007-06-06 Derivados de quinazolinona como antagonistas de cgrp PE20080370A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06011787 2006-06-08

Publications (1)

Publication Number Publication Date
PE20080370A1 true PE20080370A1 (es) 2008-06-13

Family

ID=37101671

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2007000697A PE20080370A1 (es) 2006-06-08 2007-06-06 Derivados de quinazolinona como antagonistas de cgrp
PE2007000698A PE20080153A1 (es) 2006-06-08 2007-06-06 Composicion farmaceutica que comprende un antagonista del peptido relacionado con el gen calcitonina (cgrp)

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2007000698A PE20080153A1 (es) 2006-06-08 2007-06-06 Composicion farmaceutica que comprende un antagonista del peptido relacionado con el gen calcitonina (cgrp)

Country Status (19)

Country Link
US (2) US20080139591A1 (es)
EP (2) EP2029234A1 (es)
JP (2) JP2009539800A (es)
KR (1) KR20090021214A (es)
CN (1) CN101500653A (es)
AR (2) AR061271A1 (es)
AU (1) AU2007255395A1 (es)
BR (1) BRPI0712492A2 (es)
CA (2) CA2654047A1 (es)
CL (2) CL2007001662A1 (es)
EA (1) EA200802381A1 (es)
EC (1) ECSP089025A (es)
IL (1) IL195712A0 (es)
MX (1) MX2008015562A (es)
NO (1) NO20085051L (es)
PE (2) PE20080370A1 (es)
TW (2) TW200808791A (es)
UY (2) UY30398A1 (es)
WO (2) WO2007141284A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2029234A1 (en) * 2006-06-08 2009-03-04 Boehringer Ingelheim International GmbH Treatment of gastrointestinal disorders with cgrp-antagonists
WO2010070023A2 (en) * 2008-12-19 2010-06-24 Boehringer Ingelheim International Gmbh Formulations
FR2963738B1 (fr) * 2010-08-10 2012-09-28 Assist Publ Hopitaux De Paris Compose destine au traitement des douleurs abdominales fonctionnelles
KR101965461B1 (ko) 2011-05-20 2019-04-04 앨더바이오 홀딩스 엘엘씨 필요한 대상체, 특히 편두통 환자의 광선공포증 또는 광선 혐오증을 예방 또는 억제하기 위한 항-cgrp 항체 및 항체 단편의 용도
EP2709662B1 (en) * 2011-05-20 2019-07-31 AlderBio Holdings LLC Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
CN103748111B (zh) 2011-05-20 2018-04-27 奥尔德生物控股有限责任公司 抗cgrp组合物及其用途
US20170114122A1 (en) 2015-10-23 2017-04-27 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
TWI636041B (zh) * 2015-08-12 2018-09-21 美國禮來大藥廠 Ｃｇｒｐ受體拮抗劑
GB201519196D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
GB201519194D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP receptor antagonists
GB201519195D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
EP3366286A1 (en) 2017-02-22 2018-08-29 Johannes Keller Compounds for treating sepsis
BR112020018192A2 (pt) 2019-01-08 2021-08-24 H. Lundbeck A/S Tratamento agudo e tratamento rápido de dor de cabeça com o uso de anticorpos anti-cgrp
AU2020202454A1 (en) 2020-04-06 2021-10-21 H. Lundbeck A/S Treatment of most bothersome symptom (MBS) associated with migraine using anti-CGRP antibodies

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5291960A (en) * 1992-11-30 1994-03-08 Ford Motor Company Hybrid electric vehicle regenerative braking energy recovery system
DE10250082A1 (de) 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE10250080A1 (de) * 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7595312B2 (en) * 2002-10-25 2009-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
WO2005041757A2 (en) * 2003-10-29 2005-05-12 University Of Rochester Detection of neuropeptides associated with pelvic pain disorders and uses thereof
DE102004015723A1 (de) * 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004019492A1 (de) * 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004063753A1 (de) * 2004-12-29 2006-07-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung ausgewählter CGRP-Antagonisten in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne
DE102004063755A1 (de) * 2004-12-29 2006-07-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von CGRP-Antagonisten zur Behandlung und Vorbeugung von Hitzewallungen bei Patienten mit Prostatakrebs
DE102004063752A1 (de) * 2004-12-29 2006-07-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung ausgewählter CGRP-Antagonisten zur Bekämpfung menopausaler Hitzewallungen
US7491717B2 (en) * 2005-03-23 2009-02-17 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
EP1770091A1 (de) * 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
CN101146799A (zh) 2005-03-23 2008-03-19 贝林格尔·英格海姆国际有限公司 Cgrp拮抗剂、其制备方法以及其作为药物的用途
DE102005038831A1 (de) 2005-08-17 2007-02-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
EP1770087A1 (de) * 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
EP1770086A1 (de) * 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102006017827A1 (de) * 2006-04-13 2007-10-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue kristalline Verbindungen
EP2029234A1 (en) * 2006-06-08 2009-03-04 Boehringer Ingelheim International GmbH Treatment of gastrointestinal disorders with cgrp-antagonists

Also Published As

Publication number Publication date
UY30399A1 (es) 2008-01-31
AR061272A1 (es) 2008-08-13
AU2007255395A1 (en) 2007-12-13
PE20080153A1 (es) 2008-04-14
KR20090021214A (ko) 2009-02-27
CL2007001662A1 (es) 2008-01-25
BRPI0712492A2 (pt) 2012-08-21
JP2009539800A (ja) 2009-11-19
CA2654047A1 (en) 2007-12-13
EP2029234A1 (en) 2009-03-04
NO20085051L (no) 2008-12-19
AR061271A1 (es) 2008-08-13
EA200802381A1 (ru) 2009-06-30
UY30398A1 (es) 2008-01-31
TW200815010A (en) 2008-04-01
TW200808791A (en) 2008-02-16
IL195712A0 (en) 2009-09-01
US20080139537A1 (en) 2008-06-12
WO2007141284A3 (en) 2008-03-06
CN101500653A (zh) 2009-08-05
CL2007001663A1 (es) 2008-01-25
WO2007141285A1 (en) 2007-12-13
EP2029233A2 (en) 2009-03-04
CA2654048A1 (en) 2007-12-13
US7807666B2 (en) 2010-10-05
JP2009539799A (ja) 2009-11-19
MX2008015562A (es) 2008-12-17
US20080139591A1 (en) 2008-06-12
ECSP089025A (es) 2009-01-30
WO2007141284A2 (en) 2007-12-13

Similar Documents

Publication Publication Date Title
PE20080370A1 (es) Derivados de quinazolinona como antagonistas de cgrp
ECSP088450A (es) Derivados de pirimidina 4-(3-aminopirazol) para uso como inhibidores de tirosina quinasa en el tratamiento de cáncer
CO6361936A2 (es) Imidazopiridazinacarbonitrilos utiles como inhibidores de quinasa
UY30835A1 (es) 8-alquinilxantinas y derivados
SV2007002007A (es) Compuestos de quinolina sustituidos ref. pc 25932a
SV2011003903A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa iv para el tratamiento o prevencion de diabetes
UY29300A1 (es) Compuestos quimicos
ATE482210T1 (de) Oxadiazolderivate als s1p1-rezeptor-agonisten
DOP2007000051A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes
HN2008001667A (es) Antagonistas de los receptores cgrp espirociclicos sustituidos
CR8497A (es) Derivados de azepinoindol como agentes farmaceuticos
UY28766A1 (es) Compuestos heteropolicíclicos adicionales y su uso como antagonistas del receptor de glutamato metabotrópico
UY30498A1 (es) Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones
UY28763A1 (es) Compuestos de tetrazol y su uso como antagonistas del receptor de glutamato metabotrópico
ECSP055676A (es) Piperazinas heterocíclicas sustituidas para el tratamiento de la esquizofrenia
PA8658301A1 (es) Derivados fusionados de pirazol y metodos de tratamiento de trastornos metabolicos con estos
AR060536A1 (es) Agonista del receptor de glucocorticoides y composiciones farmaceuticas
UY31281A1 (es) Aminas, benzamidas y sulfonamidas {[4-(5,6-dimetil-2-piridin-2-il-piridin-3-il) oxipiridin-2-il]amino} sustituidas, sus sales farmacéuticamente aceptables, composiciones contenniéndolas y aplicaciones.
PA8589601A1 (es) Derivados de indazol como antagonistas del crf
UY33655A (es) Co-cristales y sales de inhibidores de ccr30
GT200700075A (es) Derivados de eter diarilico y usos de los mismos
UY29092A1 (es) Derivados de 4-oxo-3,4-dihidroquinazolin-6-carboxamida, inhibidores de b-raf, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
UY29184A1 (es) Derivados de sulfonilbencimidazol
NI200700189A (es) Ciclopropil -(2,3-dimetilbencil)amidos del ácido 7-{4-[2-(2,6-dicloro-4-metilfenoxi)- etoxi]fenil}-3,9- diazabiciclo [3.3.1]non-6-en-6-carboxílico como inhibidores de renina para el tratamiento de la hipertensión.
CY1113759T1 (el) Ταχεως διασπομενοι ανταγωνιστες υποδοχεα ντοπαμινης 2

Legal Events

Date Code Title Description
FC Refusal